anlotinib + anti-PD-1 antibody

A combination therapy consisting of anlotinib, a novel oral multi-target tyrosine kinase inhibitor, and anti-PD-1 antibodies. Anlotinib inhibits vascular endothelial growth factor receptor (VEGFR) types 2 and 3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptor (PDGFR) α and β, stem cell factor receptor (c-Kit), and RET[1]. This combination creates synergistic effects by simultaneously targeting tumor angiogenesis and enhancing anti-tumor immunity. Research indicates that anlotinib can downregulate PD-L1 expression in cancer cells, which may enhance the effectiveness of anti-PD-1 therapy[4]. Additionally, anlotinib induces immunogenic cell death (ICD), elicits anti-tumor inflammation, and promotes infiltration and activation of dendritic cells and CD8+ T cells, effects that are further enhanced by anti-PD-1 antibodies[5].